Innovative Technology Cipherome's proprietary Xentinel platform leverages advanced bioinformatics and genomic analysis to predict adverse drug reactions, presenting an opportunity to collaborate with pharmaceutical companies interested in enhancing drug safety and personalized medicine.

Market Recognition Being recognized as a finalist at the AHA’s Health Technology & Innovation Competition indicates credibility and visibility in the health tech sector, facilitating potential partnership or pilot project opportunities with healthcare organizations.

Funding & Revenue With revenue between 1M to 10M and ongoing investor interest, there is a growing market demand for Cipherome’s solutions, creating sales potential with biotech, pharma, and clinical research firms seeking innovative ADR prediction tools.

Growth Potential Cipherome's location in Silicon Valley combined with a small but specialized team suggests agility and potential for scaling personalized drug safety solutions, appealing to large pharmaceutical companies investing in precision medicine.

Market Expansion Recent industry recognition and technological focus position Cipherome well to expand its client base beyond early adopters to include major healthcare providers and biotech firms aiming to reduce medication-related risks.